Teva Pharmaceutical Industries Ltd. (TEVA, Financial) experienced a significant stock price drop of 5.04%, trading at $17.61 per share with a trading volume of 20.73 million shares and a turnover rate of 1.83%. The stock's volatility reached 5.23%.
Recent financial reports reveal that Teva achieved a revenue of $4.341 billion but suffered a net loss of $437 million, translating to an earnings per share of -$0.39. The company's gross profit stood at $2.158 billion, with a price-to-earnings ratio of -12.15.
In terms of institutional ratings, 75% of the 12 participating institutions recommended buying the stock, while 25% suggested holding, with no sell recommendations.
Within the pharmaceutical sector, which saw an overall increase of 1.58%, related stocks like Mira Pharmaceuticals, Inc., Cbdmd, Inc., and Evotec Se showed significant gains. Cbdmd, Inc., Nature's Sunshine Products, and Painreform Ltd. were active, with turnover rates of 30.82%, 10.56%, and 8.21%, respectively. Stocks with notable volatility included Sunshine Biopharma Inc C/Wts, Ironwood Pharmaceuticals, and Huapont Life Sciences, with fluctuations of 36.90%, 30.65%, and 27.51%.
Teva, headquartered in Israel, is a leading generic drug manufacturer with significant sales in North America and a strong presence in Europe, Japan, Russia, and Israel. Besides generics, Teva offers innovative drugs and biosimilars in the central nervous system, respiratory, and oncology sectors. The company also sells active pharmaceutical ingredients and provides contract manufacturing services.
